It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Investigational Product for Atopic Dermatitis Patients Study

Clinical Trial Title: 
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of an Investigational Product in Atopic Dermatitis Patients Who Are Inadequately Controlled by or Intolerant to Topical Therapy
Clinical Trial Protocol ID: 
13083002
Clinical Trial Investigator Name: 
Michael D. Tharp, MD
Clinical Trial Protocol Description: 

Rush Dermatology seeks volunteers with a diagnosis of atopic dermatitis or eczema for a clinical trial testing an investigational medication. All office visits and treatments are provided free of charge.

Anticipated results are a possible new treatment option for patients with moderate to severe atopic dermatitis.

The study will last about 24 weeks with a possible extension.

Clinical Trial Eligibility Criteria: 

You may be eligible to participate in this study if you:

  • Have moderate to severe atopic dermatitis or eczema
  • Are 18 to 65 years of age
  • Have had an inadequate response to at least one topical steroid or topical calcineruin inhibitor
  • Are willing to stop current treatments
Clinical Trial Area: 
Dermatology
Contact Phone: 
(312) 563-4001
Contact Name: 
Carmen Petrizzo or Danica Uzelac